ArticleInternal medicine journal2026
Continuous positive airway pressure usage before and after issue of an urgent product defect correction notice following a global Philips recall.
Article in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFollowing the global recall of three to four million Philips continuous positive airway pressure (CPAP) devices in 2021 due to emissions of harmful products, the Therapeutic Goods Administration (TGA) issued guidance recommending continuing usage, stating discontinuing treatment could be immediately harmful. At the time of the recall, Philips devices were exclusively utilised in the subsidised CPAP programme at Austin Health.
aimThis study aims to evaluate the mean nightly usage of affected Philips CPAP devices before and after the TGA notice. (Hypothesis: Our hypothesis is that mean nightly usage of affected Philips CPAP devices decreased after the TGA notice.)
methodsAutomatically uploaded nightly CPAP usage data from a single centre 6 months prior to the TGA notice was compared with the data 6 months after using a paired t-test analysis.
resultsThere were 629 Philips pumps issued in the period before the TGA notice. Usage data were available from 368 devices. Of these, 30 devices had no usage data after the notice. The average Apnoea-Hypopnea Index was 47.7 (±25.7). Mean usage over the 6 months prior to the notice decreased by 1.33 h (±2.14) from 5.56 (±2.45) h/night to 4.23 (±3.08) with a 95% confidence interval (CI) (1.11, 1.55), P < 0.001. There was a large effect size (Cohen's d = 2.14).
conclusionThe TGA notice was associated with decreased mean nightly CPAP usage. Possibly due to concerns regarding inhalation of toxic compounds or coincidental reasons. Decreased use has implications for participant health, with function normalisation predicted with increased duration of use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.